Gastroenteropancreatic Neuroendocrine Tumors
12
1
2
8
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
16.7%
2 terminated out of 12 trials
80.0%
-6.5% vs benchmark
17%
2 trials in Phase 3/4
63%
5 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (12)
Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors
Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors
177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs
[68 Ga]-DOTANOC PET/CT in GEP-NETs
Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs
Community-based Neuroendocrine Tumor (NET) Research Study
68Ga-OPS202 Study for Diagnostic Imaging of GEP NET
Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET
Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors